Based on the Bausch + Lomb Corp stock forecast from 10 analysts, the average analyst target price for Bausch + Lomb Corp is USD 19.81 over the next 12 months. Bausch + Lomb Corp’s average analyst rating is Buy . Stock Target Advisor’s own stock analysis of Bausch + Lomb Corp is Bearish, which is based on 3 positive signals and 11 negative signals. At the last closing, Bausch + Lomb Corp’s stock price was USD 19.57. Bausch + Lomb Corp’s stock price has changed by -3.36% over the past week, -6.23% over the past month and +20.28% over the last year.
No recent analyst target price found for Bausch + Lomb Corp
No recent average analyst rating found for Bausch + Lomb Corp
Company Overview Bausch + Lomb Corp
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief. Its Pharmaceuticals segment offers proprietary and generic pharmaceutical products for post-operative treatments, as well as for the treatment of glaucoma, eye inflammation, ocular hypertension, dry eyes, and retinal diseases. The Surgical segment provides medical device equipment, consumables, and technologies for the treatment of cataracts, corneal, vitreous, and retinal eye conditions; and intraocular lenses and delivery systems, phacoemulsification equipment, and other surgical instruments and devices for cataract surgery. The company sells its products and services through direct sales forces and independent distributors. Bausch + Lomb Corporation was founded in 1853 and is headquartered in Vaughan, Canada. Bausch + Lomb Corporation operates as a subsidiary of Bausch Health Companies Inc. Address: 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4 Read Less
Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceut...Read More
Frequently Asked Questions About Bausch + Lomb Corp (BLCO) Stock
Based on ratings from 10 analysts Bausch + Lomb Corp's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on BLCO's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for BLCO is USD 19.81 over the next 12 months. The maximum analyst target price is USD 24 while the minimum anlayst target price is USD 15.5.
BLCO stock's Price/Earning ratio is 914.00.
Our analysis grades BLCO stock's Price / Earning ratio at F. This means that BLCO stock's Price/Earning ratio is above 91% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this BLCO may be a overvalued for its sector.
The last closing price of BLCO's stock was USD 19.57.
The most recent market capitalization for BLCO is USD 6.96B.
Based on targets from 10 analysts, the average taret price for BLCO is projected at USD 19.81 over the next 12 months.
This means that BLCO's stock price may go up by +1.21% over the next 12 months.
We can't find any ETFs which contains Bausch + Lomb Corp's stock.
As per our most recent records Bausch + Lomb Corp has 13,000 Employees.
Bausch + Lomb Corp's registered address is 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4.
You can get more information about it from Bausch + Lomb Corp's website at https://www.bausch.com.
Heading 1
Heading 2
Heading 3
Heading 4
Heading 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Data 1
Data 2
Data 3
Data 4
Data 5
Stock Target Advisor's Analysis
This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.
What to like
Low volatility
The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.
Underpriced compared to book value
The stock is trading low compared to its peers on a price to book value basis and is in the top quartile. It may be underpriced but do check its financial performance to make sure there is no specific reason.
Positive free cash flow
The company had positive total free cash flow in the most recent four quarters.
What not to like
Poor capital utilization
The company management has delivered below median return on invested capital in the most recent 4 quarters compared to its peers.
Poor return on assets
The company management has delivered below median return on assets in the most recent 4 quarters compared to its peers.
Overpriced compared to earnings
The stock is trading high compared to its peers on a price to earning basis and is above the sector median.
Below median dividend returns
The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.
Poor risk adjusted returns
This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.
Low market capitalization
This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.
Negative cashflow
The company had negative total cash flow in the most recent four quarters.
Low Revenue Growth
This stock has shown below median revenue growth in the previous 5 years compared to its sector
Low Earnings Growth
This stock has shown below median earnings growth in the previous 5 years compared to its sector
Highly leveraged
The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.
Overpriced on free cash flow basis
The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.
Frequently Asked Questions About Bausch + Lomb Corp (BLCO) Stock
Based on ratings from 10 analysts Bausch + Lomb Corp's stock is Buy . Stock Target Advisor's fundamental analysis is Bearish. The stock has 7 buy, sell and 6 hold ratings.
Unfortunately we do not have enough data on BLCO's stock to indicate if its a good dividend stock.
Based on targets from 10 analysts, the average taret price for BLCO is USD 19.81 over the next 12 months. The maximum analyst target price is USD 24 while the minimum anlayst target price is USD 15.5.
BLCO stock's Price/Earning ratio is 914.00.
Our analysis grades BLCO stock's Price / Earning ratio at F. This means that BLCO stock's Price/Earning ratio is above 91% of the stocks in the Medical Instruments & Supplies sector in the NYE exchange.
Based on this BLCO may be a overvalued for its sector.
The last closing price of BLCO's stock was USD 19.57.
The most recent market capitalization for BLCO is USD 6.96B.
Based on targets from 10 analysts, the average taret price for BLCO is projected at USD 19.81 over the next 12 months.
This means that BLCO's stock price may go up by +1.21% over the next 12 months.
We can't find any ETFs which contains Bausch + Lomb Corp's stock.
As per our most recent records Bausch + Lomb Corp has 13,000 Employees.
Bausch + Lomb Corp's registered address is 520 Applewood Crescent, Vaughan, ON, Canada, L4K 4B4.
You can get more information about it from Bausch + Lomb Corp's website at https://www.bausch.com.
Add to Watchlists
loading..
Thank you for Sharing your Stock Targets for BLCO !
Loading...
Please login to proceed
Sorry - extended search is only available for registered users.
